Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx as Adjuvant Treatment in Early Stage Luminal B Breast Cancer
NCT03712956Phase 2Unknown
- Sponsor
- European Institute of Oncology
- Start
- Mar 2016
- Primary completion
- Dec 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in breast cancer, sponsored by European Institute of Oncology. Primary endpoint: Feasibility of adjuvant PLD (Caelyx) at 4 months. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03712956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712956.